CAPS Medical

Company Overview

Snapshot

Founded in December 2018 by Ilan Uchitel, CAPS Medical operates with 11–50 employees. The company has raised $8.3 million across two funding rounds from four investors. In October 2025, CAPS Medical's PlasmaSure received FDA Breakthrough Device Designation.

Business overview

CAPS Medical is a medical device company developing and commercializing its NTAP System, which utilizes non-thermal atmospheric plasma (NTAP) for the selective treatment of solid tumors. This minimally invasive technology aims to precisely destroy cancerous cells while preserving healthy tissue. The company's initial clinical studies have shown promising results in non-muscle invasive bladder cancer (NMIBC) and demonstrated feasibility for additional cancers in the lungs, esophagus, stomach, and gastrointestinal tract. CAPS Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In October 2025, CAPS Medical's PlasmaSure system was granted FDA Breakthrough Device Designation. This designation signals significant regulatory validation for the company's non-thermal atmospheric plasma technology, indicating its potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases. For investors, this represents a strong de-risking event and a clear pathway toward accelerated development and market access, highlighting the company's immediate forward trajectory in the MedTech space.

Company Intelligence Q&A

What is CAPS Medical's core technology?

CAPS Medical develops the NTAP System, which uses non-thermal atmospheric plasma (NTAP) to selectively treat solid tumors by destroying cancerous cells while preserving healthy tissue.

When was CAPS Medical founded and by whom?

CAPS Medical was founded in December 2018 by Ilan Uchitel.

What significant regulatory milestone did CAPS Medical achieve recently?

In October 2025, CAPS Medical's PlasmaSure received FDA Breakthrough Device Designation, recognizing its potential to offer a more effective treatment for serious conditions.

Which investors participated in CAPS Medical's July 2020 funding round?

In July 2020, CAPS Medical received funding from Israel Investment Fund Group and Chasing Value Asset Management.

What is the primary focus of CAPS Medical's clinical studies?

CAPS Medical's clinical studies have focused on non-muscle invasive bladder cancer (NMIBC) and demonstrated the feasibility of its technology for other cancers, including those in the lungs, esophagus, stomach, and GI tract.